RPGR

RPGR stands for "retinitis pigmentosa GTPase regulator," and the gene carries instructions for a protein found in the retina's photoreceptors — the specialized cells that capture light. This protein localizes to the outer segment of rod photoreceptors and is essential for keeping those cells alive and working. For the protein to function properly, it must undergo a chemical modification called glutamylation, which is carried out by a partner enzyme known as TTLL5. RPGR lies on the X chromosome, which is why the disease it causes is described as X-linked (definition: An inheritance pattern where the altered gene is on the X chromosome. These conditions often affect males more severely, though some female carriers have symptoms too.). Changes (mutations) in RPGR account for the great majority of X-linked retinitis pigmentosa cases and are among the most frequent causes of retinitis pigmentosa overall. A large share of disease-causing changes sit in a hard-to-read region of the gene called ORF15, which standard genetic tests can miss unless the laboratory sequences the full length of the gene.

RPGR-related disease does not look identical in everyone; researchers describe three main patterns — rod-cone, cone-rod, and cone-dominated degeneration. In the rod-cone pattern, the earliest problems are usually loss of peripheral (side) vision and difficulty seeing in dim light, sometimes called night blindness. In the cone-rod pattern, central vision (used for reading and detail) tends to be affected first and symptoms often begin later in life. In one clinic series, the median age when symptoms first appeared was around 6 years for the rod-cone pattern and around 28 years for the cone-rod pattern. Many people with RPGR-related disease are also short-sighted, and high myopia is especially common in the cone-dominated forms. Over time, published studies report progressive declines in visual acuity, visual field, and retinal structure, eventually leading to blindness in affected males. Female carriers show a very wide spectrum, from a normal-appearing retina to disease as severe as that seen in males.

The link between RPGR and X-linked (definition: An inheritance pattern where the altered gene is on the X chromosome. These conditions often affect males more severely, though some female carriers have symptoms too.) retinitis pigmentosa is well established and is documented in specialist genetic references. RPGR appears repeatedly as one of the most common retinitis pigmentosa genes in studies from many different countries, including Finland, Argentina, and Poland. A two-year natural history study (definition: A study that follows people with a condition over time without giving a new treatment, to understand how the condition normally progresses.) of 201 males with RPGR-associated disease documented generally slow, measurable change across vision and retinal-imaging measures, providing careful baseline data for future treatments. A systematic review of published progression data confirmed steady annual declines in visual acuity, visual field, and the retina's ellipsoid zone. There is a recognized genotype (definition: A person's specific genetic makeup — which gene and which variant is causing their condition — as opposed to the phenotype, the symptoms it produces.)-phenotype (definition: The observable traits or symptoms a condition actually produces in a person — as opposed to the genotype, the underlying genetic cause.) relationship: variants toward the distal end of the ORF15 region tend to produce cone-dominant disease, while more proximal variants tend to produce rod-cone disease. In female carriers, the severity of disease is closely tied to X-chromosome inactivation, the natural process by which one X chromosome is switched off in each cell; heavily skewed inactivation is associated with more severe symptoms.

Even with the same genetic change, the age of onset, pattern, and speed of vision loss vary from person to person, so an individual's future course cannot be predicted from the gene result alone. It remains especially hard to predict how, or whether, a female carrier will be affected. In one study, the degree of short-sightedness was not clearly tied to the exact position of the mutation, so the reasons some patients develop high myopia are not fully understood. For gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.), early results are encouraging but the studies so far are small and short, and reviewers stress that larger, longer trials are needed to understand lasting benefit and risk.

No therapy specifically targeting RPGR has been approved to date, and current everyday care focuses on supportive measures such as visual aids and correcting refractive error. The most actively studied approach is gene augmentation therapy, which uses a harmless adeno-associated virus (AAV) to deliver a working copy of RPGR into photoreceptors. Developing this therapy has been technically difficult because the RPGR gene, particularly ORF15, is unstable and hard to reproduce faithfully in a vector. A published Phase 1/2 trial of one AAV-RPGR product reported a manageable safety profile and improvements in retinal sensitivity and functional vision compared with untreated eyes, supporting further study. Pooled analyses of the trials so far suggest real short-term functional benefit for many participants, but also a notable rate of eye inflammation and raised eye pressure that must be watched closely, especially at higher doses. Laboratory work in human retinal organoids and in animal models continues to clarify how restoring RPGR helps photoreceptors, but these are research findings, not available treatments.

• Phase 1/2 trial of an AAV-RPGR gene therapy

  Early-phase interventional clinical trial

  What was found:

  The therapy was generally well tolerated, with mostly transient surgery-related side effects and a few serious but manageable events, and treated eyes showed improvements in retinal sensitivity and functional vision compared with untreated eyes.

  Why it matters:

  It provided the safety and early efficacy basis for advancing this approach toward a Phase 3 trial.

  Limitation: It was a small, open-label study with follow-up of about a year, so long-term durability and benefit remain to be proven.

• Why some female carriers of RPGR mutations develop disease

  Laboratory and cellular research within a family study

  What was found:

  Differences in which X chromosome was switched off in cells (X-inactivation) correlated with RPGR expression and with whether carriers showed disease.

  Why it matters:

  It helps explain the wide variability among female carriers and underscores why carrier relatives may warrant eye evaluation.

  Limitation: It centered on a single family and small numbers of cell lines, so conclusions are suggestive rather than definitive.

• A two-year natural history study of RPGR-associated X-linked RP

  Prospective observational human study (natural history)

  What was found:

  Changes across most measures were small over two years, indicating slow measurable progression, and there were no ocular serious adverse events during observation.

  Why it matters:

  Careful natural history data give clinicians and trial designers a baseline against which any future treatment effect can be judged.

  Limitation: Only males with a certain range of vision were included, and two years is short relative to a disease that unfolds over decades.

• Systematic review of disease progression in RPGR-associated XLRP

  Systematic review of human studies

  What was found:

  Studies consistently reported yearly declines in visual acuity, visual field, and the ellipsoid zone, with progression eventually leading to blindness.

  Why it matters:

  It confirms the progressive, serious nature of the condition and highlights the need for standardized long-term measures.

  Limitation: The underlying studies used different methods and definitions, and patient-reported outcome data were limited.

• Meta-analysis of AAV-RPGR gene therapy safety and efficacy

  Systematic review and meta-analysis of human trials

  What was found:

  A majority of participants showed improvement in retinal sensitivity, about half showed visual function improvement, and roughly two in five experienced adverse events including intraocular inflammation and raised eye pressure, more so at higher doses.

  Why it matters:

  It gives a balanced, combined picture of both the promise and the risks that current gene therapy carries.

  Limitation: The included studies were small and varied, and pooling such data can overstate consistency.

Because RPGR is X-linked (definition: An inheritance pattern where the altered gene is on the X chromosome. These conditions often affect males more severely, though some female carriers have symptoms too.), the inheritance pattern has specific meaning for relatives: mothers of an affected male are often carriers, sons of a carrier have a chance of being affected, and daughters of a carrier may be carriers themselves. Female carriers are not always symptom-free — some develop meaningful vision loss — so a family history that looks absent or looks like it skips around does not rule out X-linked inheritance, and evaluation of at-risk female relatives can be worthwhile. Symptoms often begin in childhood, and because high myopia is common, attention to a child's vision correction and eye care can be an important part of ongoing management.

• Did my genetic test sequence the full length of RPGR, including the ORF15 region?
• Based on my variant and exam, does my disease look more like the rod-cone, cone-rod, or cone-dominated pattern?
• How is my myopia being monitored and managed, given how common it is in RPGR-related disease?
• What imaging or functional tests would help track my progression over time?
• If I am a female relative or carrier, what monitoring is recommended for me?
• Are there RPGR-focused clinical trials or natural history studies I might consider discussing further?

Because a large fraction of RPGR variants sit in the ORF15 region that ordinary panels can miss, it may be worth confirming that any genetic testing sequenced the full length of the gene. Genetic counseling can help interpret your specific variant and what it may mean for relatives. If you are interested in research studies, RP Hope's Clinical Trials Finder can help you screen for options with RPGR preselected. RP Hope's guided pathway and patient stories can help you find resources and community as you navigate a diagnosis.